RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests a combination of four drugs (zanubrutinib, rituximab, lenalidomide, and tislelizumab) in 33 adults with follicular lymphoma that has returned or not responded after at least two prior treatments. Participants receive 6 cycles of the combination, then those who re…
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New hope for Tough-to-Treat lymphoma: mosunetuzumab under review
Disease control Recruiting nowThis study looks at how well the drug mosunetuzumab works for people with follicular lymphoma that has come back or not responded to at least two prior treatments. Researchers will review medical records from 25 patients who received the drug through a compassionate use program. …
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Sponsor: Andrés José Maria Ferreri • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New hope for Tough-to-Treat lymphomas: experimental combo enters phase 3 trial
Disease control Recruiting nowThis study tests an experimental drug, odronextamab, combined with lenalidomide in people whose follicular or marginal zone lymphoma has returned or not responded to prior treatment. The trial has two parts: first to find a safe dose, then to compare the new combo against the sta…
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New hope for lymphoma patients: drug combo trial launches
Disease control Recruiting nowThis study compares two drug combinations for people with follicular or marginal zone lymphoma that has come back or not responded to prior treatment. About 780 participants will receive either zanubrutinib plus an anti-CD20 antibody or lenalidomide plus rituximab. The goal is to…
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated May 13, 2026 16:03 UTC